Primary Graft Dysfunction After Heart Transplantation for Chagas Disease With Refractory Electrical Storm Authors: Rafael Alejandro Iraheta Castaneda, Daniel Manzur Sandoval, David Jacobo Sánchez Amaya, Luis Antonio Morgado Villaseñor, Nadia Melisa Queb Pech, Rafael Magaña González, Itzel Elena Portillo Yáñez Published: 2026 ABSTRACT AbstractBackgroundElectrical storm in Chagas disease represents a life-threatening scenario, particularly in Latin America.Case SummaryA 62-year-old man developed recurrent ventricular tachycardia a decade after implantable cardioverter-defibrillator placement for Chagas cardiomyopathy. Despite optimized therapy, arrhythmia control was not achieved, culminating in refractory electrical storm. He underwent heart transplantation. Severe primary graft dysfunction developed intraoperatively. Peripheral venoarterial extracorporeal membrane oxygenation was initiated, unloading with an intra-aortic balloon pump and direct left atrial drainage, achieving successful recovery.DiscussionManagement of refractory electrical storm is complex and may require mechanical circulatory support. Heart transplantation is a therapeutic option. When primary graft dysfunction occurs, venoarterial extracorporeal membrane oxygenation provides effective support, particularly when combined with active unloading.Take-Home MessagesHeart transplantation should be considered for refractory electrical storm in Chagas disease. Severe primary graft dysfunction is a major complication that could be reversed with structured, physiology-guided support.Key words: Chagas cardiomyopathy, electrical storm, heart transplantation, primary graft dysfunction, VA-ECMO History of presentation A 62-year-old man, born in El Salvador and residing in Mexico, first presented in 2012 with palpitations and diaphoresis. Electrocardiography showed nonsustained ventricular tachycardia (VT) that responded to pharmacologic therapy. Chagas heart disease was diagnosed serologically, and an implantable cardioverter-defibrillator (ICD) was placed. Electrophysiological study documented sustained epicardial VT originating from the anterior left ventricular (LV) wall. Unsuccessful epicardial ablation was attempted in 2017. ICD generator replacement occurred in 2021. Take-Home Messages •Primary graft dysfunction requires early recognition and prompt implantation of mechanical circulatory support. Primary graft dysfunction requires early recognition and prompt implantation of mechanical circulatory support. •Management decisions should be guided by structured, physiology-based assessment. Management decisions should be guided by structured, physiology-based assessment. •Chagas disease may lead to a refractory electrical storm; in patients unresponsive to conventional therapy, heart transplantation should be considered. Chagas disease may lead to a refractory electrical storm; in patients unresponsive to conventional therapy, heart transplantation should be considered. Past medical history, differential diagnosis and investigations Heart failure developed (LV ejection fraction: 40%) alongside primary hypothyroidism. Guideline-directed medical therapy included amiodarone, sacubitril/valsartan, spironolactone, furosemide, metoprolol succinate, atorvastatin, and levothyroxine. In November 2024, he presented with multiple ICD antitachycardia pacing and shocks for VT. He reported palpitations and presyncopal episodes. On physical examination, he presented with diaphoresis, cold skin, blood pressure of 105/65 mm Hg, and a variable heart rate ranging from 85 to 160 beats/min. Management Intravenous amiodarone, esmolol, lidocaine, and magnesium failed to terminate the arrhythmia. Deep sedation, mechanical ventilation, and a diagnosis of electrical storm (ES) ensued. Bilateral stellate ganglion blockade restored sinus rhythm. He was discharged but re-presented 3 times over the next 2 months, requiring external cardioversion and medication adjustments. In late January 2025, recurrent VT prompted readmission (Figure 1A), pharmacological treatment achieved control for a brief period using amiodarone, lidocaine, and esmolol; A repeat electrophysiological study with Carto (J&J Med Tech)–guided endocardial ablation of the inferolateral LV wall failed. Ongoing deterioration led to listing for emergent heart transplantation (HTx) given refractory ES. After 9 days, a donor aged <40 years with normal LV ejection fraction and matched height/sex became available, and transplantation proceeded under emergency allocation. Induction comprised basiliximab, methylprednisolone, and mycophenolate mofetil. Bicaval orthotopic HTx was performed (ischemic time: 140 min). Initial weaning from cardiopulmonary bypass failed owing to mixed vasoplegic-cardiogenic shock (low cardiac index, elevated left filling pressures, and low vascular resistance). Reinitiation of cardiopulmonary bypass and maximal inotropic/vasopressor support (dobutamine, levosimendan, norepinephrine, vasopressin, epinephrine) were necessary, with lactate 11 mmol/L and severe metabolic acidosis. Transesophageal echocardiography demonstrated severe biventricular dysfunction. Multipanel Image of the Case (A) Admission electrocardiogram before heart transplantation showing sustained ventricular tachycardia (red arrow). (B) Transesophageal echocardiography during VA-ECMO without unloading devices demonstrating spontaneous echo contrast, absence of aortic valve opening, and left ventricular distension (blue arrow). (C) Chest radiograph at ICU admission showing positions of ECMO cannulas, left atrial drainage cannula, and intra-aortic balloon pump. (D) Transthoracic echocardiography at ICU discharge demonstrating recovery of left ventricular systolic function (ejection fraction: >50%) (yellow arrow). ICU = intensive care unit; VA-ECMO = venoarterial extracorporeal membrane oxygenation. Severe biventricular primary graft dysfunction (PGD) was diagnosed, mandating peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) via left femoral cannulation with placement of a distal perfusion cannula, as routinely performed at our center. Absent pulse pressure and intermittent aortic valve opening persisted (Figure 1B); therefore, an intra-aortic balloon pump (IABP) was placed through the right femoral artery. Persistently elevated LV filling pressures, dilated left ventricle, and noncontinuous aortic valve opening prompted placement of a 14-F left atrial (LA) drainage cannula for venting (Figure 1C). At that time in the operating room, septostomy for left atrial venting was not available. This achieved aortic valve opening with each beat and reduced filling pressure. Despite mechanical support, high vasopressor doses were required (peak norepinephrine: 0.5 μg/kg/min; vasopressin: 0.14 IU/min; epinephrine: 0.2 μg/kg/min). Deep sedation was maintained. Maintenance immunosuppression consisted of prednisone, tacrolimus, and mycophenolate mofetil; nifurtimox was added for Trypanosoma cruzi suppression. Both unloading devices were preserved; neither of them alone achieved adequate opening of the aortic valve. Within 48 hours, hemodynamics stabilized and vasoactive agents were tapered. After 96 hours, the LA vent was removed. We preferred to remove the LA vent first, as there was no compromise in limb perfusion and it allowed maintenance of minimal mechanical support with the IABP. Low-dose vasopressors/inotropes continued. On day 5, the IABP was explanted and VA-ECMO flow was reduced to 0.5 L/min. Transthoracic echocardiography showed an LV outflow tract velocity-time integral of 14 cm and pulse pressure of 44 mm Hg—favorable weaning parameters. Levosimendan (0.1 μg/kg/min) was restarted to facilitate separation, and VA-ECMO was discontinued after 6 days of support (Table 1). At our institution, severe PGD is treated with VA-ECMO, with cannulation strategies individualized for each case and guided by physiology-based principles. Table 1Post-Transplant Hemodynamics and Support ParametersPost-TransplantStart of VA-ECMODay 1Day 2Day 3Day 4Day 4 (Later)Day 5Native CI (L/min/m2)1.01.11.21.51.781.781.92.1ECMO flow (L/min)—3.034.54.54.01.61.00.5 (weaning)PWP (mm Hg)2220191515141412CVP (mm Hg)1917151210111110Pulse pressure (mm Hg)129304035494544Aortic valve openingYesIntermittent (before unloading)YesYesYesYesYesYesITV LVOT (cm)6577781114Lactate (mmol/L)11721.81.01.51.21.1Norepinephrine (μg/kg/min)0.50.30.570.380.120.090.15—Vasopressin (U/min)0.050.060.060.080.050.050.03—Epinephrine (μg/kg/min)0.30.20.080000—Dobutamine (μg/kg/min)1010157.5885—Levosimendan (μg/kg/min)0.20.20.10.15000.10.1IABP—1:11:11:11:11:2Weaning—Drainage of left cavities—YesYesYesYesWithdrawal——CI = cardiac index; CVP = central venous pressure; ECMO = extracorporeal membrane oxygenation; IABP = intra-aortic balloon pump; ITV LVOT = velocity-time integral in left ventricular outflow tract; PWP = pulmonary wedge pressure. Post-Transplant Hemodynamics and Support Parameters CI = cardiac index; CVP = central venous pressure; ECMO = extracorporeal membrane oxygenation; IABP = intra-aortic balloon pump; ITV LVOT = velocity-time integral in left ventricular outflow tract; PWP = pulmonary wedge pressure. Outcome and follow-up Elective extubation followed a successful spontaneous-breathing trial; high-flow nasal oxygen was instituted. The patient experienced delirium without additional organ injury and was transferred from the intensive care unit after a 16-day stay (Figure 1D). Later, he developed surgical wound infection at the ECMO cannulation sites. The ICD was removed electively during hospitalization, and he was discharged 42 days after HTx. Six months after transplantation he had recovered a normal life, without disabilities, and no complications related to HTx. Discussion Chagas heart disease, a chronic inflammatory cardiomyopathy,1 is one of the leading etiologies of end-stage heart failure in Latin America and confers higher mortality than other causes.2 Ventricular arrhythmias are frequent in Chagas disease.3 Their management relies on ICDs and antiarrhythmic drugs. ES, defined as ≥3 episodes of sustained ventricular arrhythmias within 24 hours, is common in Chagas disease patients with ICDs; it profoundly impairs quality of life.3 Fewer than 1% of HTx worldwide are performed for refractory ES.4 Recipients transplanted for ES have higher complication rates and lower 1-year survival; PGD is one of the main adverse events.5 Chagas disease produces diffuse myocarditis involving conduction tissue and autonomic innervation, predisposes to malignant arrhythmias. ES affects approximately 52% of Chagas disease patients with ICDs.3 Risk factors include advanced age, QRS prolongation, chronic kidney disease, prior history of arrhythmias, suboptimal medical therapy, and reduced LV ejection fraction. In this case, arrhythmic episodes and depressed LV ejection fraction were evident. Although triggers are often elusive, poor adherence to therapy precipitated 42% of ES episodes in a Latin American cohort.3 ES management requires a multidisciplinary approach.4 ICD interrogation and reprogramming are essential; intravenous class I/III antiarrhythmics are the first-line therapy. Data suggest intravenous procainamide is most effective for VT termination, followed by amiodarone, but contraindications in decompensated heart failure and chronic kidney disease render amiodarone the default.4 Lidocaine augmentation is common when amiodarone fails. Sympathetic modulation is equally critical: beta-blockade—preferably with nonselective agents—decreases arrhythmic burden.4 Refractory cases necessitate deep sedation, mechanical ventilation, stellate ganglion blockade, and catheter ablation. When hemodynamic instability precludes mapping, temporary mechanical circulatory support buys time for definitive therapy.4 In this patient, maximal escalations failed, prompting emergent HTx. Although <1% of HTx are performed for ES,4,5 organ allocation systems prioritize such emergencies.5 Nevertheless, 30-day mortality in this subgroup reaches 28%, and 1-year survival is approximately 69%. Post-HTx mechanical circulatory support is needed in around 40% of patients.5 HTx in Chagas disease requires a tailored management approach. At our center, nifurtimox is continued to reduce the risk of T cruzi reactivation, and post-transplant surveillance is performed serially using parasitological testing. Primary graft dysfunction PGD–severe ventricular dysfunction arising <24 hours post-HTx without secondary causes is a leading early killer.6 Risk factors include pretransplant LV assist device, ischemic time >4 hours, older donor age, sex mismatch, and pre-HTx dialysis.7 None were present in the present case; however, chronic amiodarone exposure may heighten PGD risk.6 ES per se is not linked to PGD, but it increases post-HTx ECMO use.5 There is no clear link between HTx in Chagas disease and PGD. Most of the experience with HTx for Chagas disease comes from South America, and, to date, there is no established physiological explanation for the development of PGD in this population. A chronic inflammatory state, autoimmunity, and frequent ventricular arrhythmias and their treatment may be contributing factors, but further studies are needed. VA-ECMO and LV unloading VA-ECMO is the preferred mechanical circulatory support for severe PGD because it supports both ventricles and oxygenates blood.8 Cannulation strategy influences outcomes. Peripheral cannulation is currently favored because it reduces bleeding and improves 1-year survival rates, albeit at the cost of limb ischemia and increased LV afterload.9 In this case, a peripheral cannulation strategy was selected to reduce bleeding risk and minimize mediastinal manipulation in the immediate post-transplant setting. The chest was primarily closed, and no bleeding complications occurred. Excess afterload elevates myocardial oxygen demand, impedes LV recovery, and may delay weaning. LV unloading—pharmacologic (inotropes, vasodilators) or mechanical (IABP, microaxial pump, surgical vent, transseptal LA drainage)—counteracts these effects.10 No single unloading strategy has demonstrated clear superiority; therefore, patient-specific factors, resource availability, and procedural risk must guide selection. Early unloading (<2 hours of ECMO initiation) could lower mortality.10 Target hemodynamics include pulmonary capillary wedge pressure ∼15 mm Hg, visible aortic valve opening, and pulse pressure ∼10 mm Hg.10 In this case, peripheral VA-ECMO plus IABP failed to normalize LV pressures, necessitating direct LA drainage. Combined unloading achieved adequate pulse pressure and aortic valve opening, enabling weaning after 6 days. Conclusions Refractory ES in Chagas disease may be life threatening. When catheter ablation and advanced antiarrhythmic strategies fail, emergent HTx remains a valid—if high-risk—salvage option. PGD complicates nearly one-third of such cases and often necessitates VA-ECMO. Peripheral cannulation with timely LV unloading can stabilize hemodynamics, limit myocardial injury, and permit recovery. This case illustrates that aggressive, protocolized support—tailored to physiologic targets—can convert a catastrophic presentation into an acceptable postoperative course. Nonetheless, robust evidence is lacking; prospective studies are imperative to refine mechanical circulatory support algorithms and improve survival in this challenging population. Ethics Statement The local research and institutional ethics committees waived approval for this study. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Visual SummaryTimeline of the CaseTimeEvent2-mo before admissionA 62-year-old man with Chagas heart disease presented with his first episode of electrical storm. He underwent pharmacological treatment, deep sedation, and bilateral stellate ganglion blockade which was successful, and he was discharged.Day of admissionRecurrent ventricular tachycardia occurred, with only brief control using pharmacological therapy.Day 5Electrophysiological study with Carto-guided endocardial ablation failedDay 6The patient was emergent listed for heart transplantation.Day 15 (post-transplant day 0)Orthotopic bicaval heart transplant was performed, severe shock and primary graft dysfunction developed. VA-ECMO with IABP and direct left atrium drainage was initiated.Day 17 (post-transplant day 2)Hemodynamic stabilization: vasopressors were weaned.Day 19 (post-transplant day 4)LA vent was removed.Day 20 (post-transplant day 5)IABP and ECMO were removed.Day 21 (post-transplant day 6)The patient was electively extubated.Day 31Discharged from intensive care unit.Day 57Discharged from hospital.IABP = intra-aortic balloon pump; LA = left atrium; VA-ECMO = venoarterial extracorporeal membrane oxygenation. Timeline of the Case IABP = intra-aortic balloon pump; LA = left atrium; VA-ECMO = venoarterial extracorporeal membrane oxygenation. Acknowledgments The authors acknowledge all the staff of the Cardiovascular Critical Care Unit of the Instituto Nacional de Cardiología Ignacio Chávez. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References